Clinical Trials Logo

Clinical Trial Summary

Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03266653
Study type Interventional
Source New York Medical College
Contact Mitchell Cairo, MD
Phone 914-594-2150
Email mitchell_cairo@nymc.edu
Status Recruiting
Phase Phase 2
Start date July 7, 2020
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT01256853 - Modified Vaccinia Ankara (MVA) Vaccine Study Phase 1
Completed NCT00070785 - Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations N/A
Recruiting NCT01248598 - The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis N/A
Completed NCT00701922 - Surveillance Study of Viral Infections Following Lung Transplantation N/A
Recruiting NCT02580539 - A Study of the Safety and Efficacy of EBV Specific T-cell Lines Phase 1/Phase 2
Completed NCT03546101 - Early Detection of Epstein-Barr Virus Related Disease.
Recruiting NCT05183490 - R-MVST Cells for Treatment of Viral Infections Phase 1
Completed NCT00058812 - Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts Phase 1
Completed NCT01094405 - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy Phase 2
Terminated NCT05305040 - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Phase 2/Phase 3
Completed NCT02335437 - Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents N/A
Completed NCT06002802 - Study on Infectious Mononucleosis in Munich
Recruiting NCT04507477 - Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial Phase 1/Phase 2
Completed NCT00963248 - EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients N/A
Enrolling by invitation NCT06027879 - Anti-viral T-cell Therapy by Gamma Capture Phase 1/Phase 2
Recruiting NCT05592626 - A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02715752 - A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin N/A
Completed NCT01070797 - Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) Phase 1
Completed NCT00058604 - Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). Phase 1
Completed NCT00058591 - Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) Phase 1